FDA Grants First Tumor-Agnostic Approval for RET Fusion-Positive Cancers

September 22, 2022 9:49 am

by Mike Bassett

— Selpercatinib approved for advanced or metastatic solid tumors that progress on systemic therapy

The FDA granted accelerated approval to selpercatinib (Retevmo) for adults with locally advanced or metastatic solid tumors associated with RET gene fusions, the

Read more

FDA Approves Tafinlar Plus Mekinist for Patients With BRAF V600-Mutant Solid Cancers

June 23, 2022 10:56 am

by Brielle Benyon

Tafinlar plus Mekinist is now approved by the Food and Drug Administration to treat adults and children over the age of 6 who have BRAF V600-mutant advanced solid cancers.

The Food and Drug Administration (FDA) approved Tafinlar

Read more

MD Anderson Researchers Present Encouraging Results of Early-Stage Clinical Trials at 2022 ASCO Annual Meeting

June 7, 2022 10:45 am

by University of Texas M.D. Anderson Cancer Center

Newswise — CHICAGO ― Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for … Read more

Biomarkers May Identify Ovarian Cancer Patients Who Benefit From AstraZeneca WEE1 Inhibitor

June 5, 2022 9:55 am

by Caroline Hopkins

CHICAGO – AstraZeneca’s investigational WEE1 inhibitor adavosertib showed potential in biomarker-selected advanced ovarian cancer populations in two studies presented during the American Society of Clinical Oncology’s annual meeting Saturday.

The drug, which AstraZeneca licensed from Merck in … Read more

Repare Therapeutics’ RP-3500 Shows Potential of ATR Inhibitors in Precision Oncology

November 4, 2021 11:09 am

by Alison Kanski

NEW YORK – Pharma companies are racing to develop oral ATR inhibitors that present a unique pan-cancer market opportunity.

Researchers reported positive Phase I results on one of these drugs, Repare Therapeutics’ RP3500, last month across tumor … Read more

Yale Cancer Center Study Shows New Strategy to Fight Drug Resistance in HER2-Positive Breast and Ovarian Cancers

October 28, 2021 11:00 am

by Anne Doerr

New findings by researchers at Yale Cancer Center demonstrate a novel strategy to treat tumor growth in breast and ovarian cancers characterized by HER2 gene amplification, an increase in the number of copies of a gene. Gene … Read more

Pertuzumab/Trastuzumab Demonstrates Activity in Tissue-Agnostic Trial for Patients With HER2-Positive Tumors

June 4, 2021 10:34 am

Results from the phase II MyPathway basket trial found that the HER2-targeted therapies pertuzumab and trastuzumab demonstrated durable activity in patients with a wide variety of tumors marked by HER2 amplification or overexpression, although responses were limited in those with … Read more

‘Virtual Biopsies’ Could Replace Tissue Biopsies in Future Thanks to Technique Developed by Cambridge Scientists

January 6, 2021 5:00 am

A new advanced computing technique using routine medical scans to enable doctors to take fewer, more accurate tumour biopsies, has been developed by cancer researchers at the University of Cambridge. This is an important step towards precision tissue sampling for

Read more

SEngine Precision Medicine IDs Potential Ovarian Cancer Treatment Combos Using Organoid Approach

November 23, 2020 8:00 pm

By Caroline Hopkins

Using organoids that closely model certain features of ovarian tumors, researchers have identified and tested treatment combinations that may benefit patients, many of whom experience acquired or de novo resistance to PARP inhibitors.

In a study recently … Read more

Large Genomics Study Points the Way to Future Cancer Clinical Trials

October 14, 2020 11:00 am

By Angus Liu

Many oncology researchers and practitioners scrutinize genetic alterations in cancer, but they either focus on one particular tumor type or one mutation that occurs across tumors. A large-scale study focusing on precision medicine in cancer is now … Read more

A Common Plant Virus Is an Unlikely Ally in the War on Cancer

October 5, 2020 3:00 pm

Researchers have seen promising results by injecting dog and mouse tumors with the cowpea mosaic virus. Now they’re aiming for a human trial.

By Daniel Oberhaus

Jack Hoopes spends a lot of time with dying dogs. A veterinary radiation specialist
Read more

Bayer’s ATR Inhibitor May Benefit Cancers With ATM Aberrations, Early Data Suggest

September 29, 2020 4:00 pm

Researchers are optimistic that data from a first-in-human clinical trial of Bayer’s ATR-inhibiting agent, BAY-1895344, may pave the way for a new class of precision oncology treatments for patients with certain DNA damage response (DDR) defects in their tumors.

The … Read more

Genetically Definable Subgroups of Cancers Sensitive to Treatment

October 24, 2019 5:00 pm

Precision oncology aims to use genetic features of a patient’s tumor to tailor anti-cancer therapy. DNA mutations in a drug target have provided a number of therapeutic opportunities; however, there are many cancer types that do not have obvious targetable … Read more

Liquid Biopsies Can Point to Best Ovarian Cancer Treatment

May 6, 2019 4:00 pm

DNA shed by tumors into the bloodstream is starting to be used for the early detection of cancer and for monitoring how well treatment is working. Such DNA, which is called circulating tumor DNA (ctDNA), hasn’t been quite as helpful

Read more

SXSW Panel: ‘Frontiers of Cancer: Racing Toward A Cure’

March 9, 2019 6:00 pm

Clearity’s Executive Director, Hillary Theakston, spoke on a panel of industry leaders at SXSW on ‘Frontiers of Cancer: Racing Toward A Cure’. Hillary, along with fellow panelists Amy Puliafito, Bobbie Rimel, MD, and Karl Handelsman discussed major investments, … Read more

AI Predicts Ovarian Cancer Survival Rates From CT Scans

February 15, 2019 5:00 pm

By Melissa Rohman

AI can predict a woman’s survival rate and response to treatments for ovarian cancer more accurately than current methods, according to research published online Feb. 15 in Nature Communications. 

The machine learning software developed by researchers at … Read more

Many Americans Unaware of Promise of Targeted, ‘Personalized’ Medicine

December 7, 2018 7:00 pm

By Dennis Thompson

Medical science has made tremendous advances in “personalized medicine” — drugs that fight cancer and other diseases by boosting the immune system or targeting specific genetic traits.

Former U.S. President Jimmy Carter benefited from one of these

Read more

Open Source Tool Predicts Chemo Drugs Best Suited for Individual Patients

November 12, 2018 12:09 am

Researchers at Georgia Institute of Technology (Georgia Tech) have developed a new open-source decision support tool designed to help clinicians chose the chemotherapy drug best suited for individual patients.

The open-source support vector machine (SVM)-based algorithm predicted the chemotherapy drug … Read more

Taking A Wider View Of Precision Oncology

August 6, 2018 11:06 pm

Proponents of precision medicine cite the growing numbers of successful precision cancer drugs. The examples of Herceptin (trastuzumab), Gleevec (imatinib mesylate), Xalkori (crizotinib), and Zelboraf (vemurafenib) come to mind. Skeptics, on the other hand, focus on the … Read more

Treating Ovarian Cancers by Targeting Mutations

July 31, 2018 11:22 pm

New research has shown that ovarian cancer patients with a tumor mutation in the BRAF gene respond exceptionally well to treatment with targeted drugs, known as BRAF inhibitors.

BRAF inhibitors block the activity of mutated BRAF gene. They are currently … Read more